For: | Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World J Gastrointest Surg 2022; 14(6): 528-537 [PMID: 35979416 DOI: 10.4240/wjgs.v14.i6.528] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v14/i6/528.htm |
Number | Citing Articles |
1 |
Arash Najafi. Commentary on “Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness”. CardioVascular and Interventional Radiology 2024; 47(7): 978 doi: 10.1007/s00270-024-03794-x
|
2 |
Landon L. Chan, Stephen L. Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment. Clinical and Molecular Hepatology 2023; 29(4): 909 doi: 10.3350/cmh.2023.0114
|
3 |
Imam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, Kakil Rasul, Jafar Bani‐Issa, Wael Abdel‐Razek, Ashraf Omar, Amr Shafik, Salem Eid, Amr Abdelaal, Ahmed Hosni, Gamal Esmat. Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region. Liver International 2023; 43(10): 2062 doi: 10.1111/liv.15685
|
4 |
Xinhao Wang, Yefa Yang. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases. Medicine 2024; 103(20): e38174 doi: 10.1097/MD.0000000000038174
|
5 |
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology 2023; 20(12): 864 doi: 10.1038/s41571-023-00825-3
|
6 |
Liyan Huang, Qinqin Long, Qunying Su, Xiaoying Zhu, Xidai Long. Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis. Exploration of Targeted Anti-tumor Therapy 2023; : 780 doi: 10.37349/etat.2023.00167
|
7 |
Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1178428
|